icotrokinra

News

J&J shows its confidence in oral IL-23 drug for psoriasis

J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.

News

J&J plots filings after psoriasis drug clears phase 3 test

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

News

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable ef

J&J shows its confidence in oral IL-23 drug for psoriasis

J&J plots filings after psoriasis drug clears phase 3 test

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks